Assessment of the effect of lupus anticoagulant on thrombotic complications in patients with new coronavirus infection. Literature review

The new coronavirus infection is accompanied by pronounced hypercoagulation changes in the haemostasis system, which have received the specific name of COVID-19-associated coagulopathy, which provokes the development of thrombosis of various localizations and is often accompanied by autoimmune disorders, in particular, the appearance of lupus-type antiphospholipid antibodies – lupus anticoagulant (LA). Despite the fact that LA is not associated with the severity of COVID-19 and in the vast majority of cases they were not detected during the recovery period, it can be assumed that their presence in the acute period of the disease may be an additional risk factor for thrombotic episodes. Aim. To assess the effect of lupus anticoagulant on thrombotic complications in patients with novel coronavirus infection based on scientific publications.